OraSure Gets $109 Million DoD Contract for Rapid COVID-19 Tests

OraSure Technologies has been awarded a $109 million contract by the Department of Defense to build additional U.S. manufacturing capacity for its InteliSwab COVID-19 rapid tests.

An existing OraSure location in Bethlehem, Pa. will be retrofitted and an additional new facility will be added in another U.S. location that is yet to be determined, the company said.

The federal funding will expand OraSure’s production capacity by 100 million tests annually by March 2024.

The FDA granted the InteliSwab tests emergency use authorizations in June for professional point-of-care use, prescription home use, and over-the-counter use.